Dr. Oaknin on the Rationale for the GARNET Trial in Endometrial Cancer

Ana Oaknin, MD
Published: Tuesday, Oct 08, 2019



Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the rationale for the phase I/II GARNET trial in endometrial cancer.

Patients with endometrial cancer can have tumors that are microsatellite stable (MSS) or microsatellite instability–high (MSI-H). However, the anti–PD-1 therapy pembrolizumab (Keytruda) is FDA approved for patients with MSI-H solid tumors, not MSS solid tumors. As such, the GARNET trial was designed to evaluate the efficacy of anti–PD-1 agents specifically in all-comers with endometrial cancer, says Oaknin.

Although MSI-H tumors have shown a particular amenability to immunotherapy, data suggest that both MSS and MSI-H respond to anti–PD-1 therapy. For example, in a phase II trial (NCT02501096) that evaluated the combination of pembrolizumab and lenvatinib (Lenvima), investigators reported responses in both patient populations, irrespective of MSI status.
SELECTED
LANGUAGE


Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the rationale for the phase I/II GARNET trial in endometrial cancer.

Patients with endometrial cancer can have tumors that are microsatellite stable (MSS) or microsatellite instability–high (MSI-H). However, the anti–PD-1 therapy pembrolizumab (Keytruda) is FDA approved for patients with MSI-H solid tumors, not MSS solid tumors. As such, the GARNET trial was designed to evaluate the efficacy of anti–PD-1 agents specifically in all-comers with endometrial cancer, says Oaknin.

Although MSI-H tumors have shown a particular amenability to immunotherapy, data suggest that both MSS and MSI-H respond to anti–PD-1 therapy. For example, in a phase II trial (NCT02501096) that evaluated the combination of pembrolizumab and lenvatinib (Lenvima), investigators reported responses in both patient populations, irrespective of MSI status.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x